AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 3 clinical trial titled ‘A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)’. The study aims to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) as a neoadjuvant treatment in patients with high-risk, HER2-positive early-stage breast cancer.
The trial is testing three interventions: T-DXd monotherapy, T-DXd followed by THP, and a standard treatment regimen of ddAC-THP. These interventions are designed to assess the potential benefits of T-DXd in improving treatment outcomes for this specific patient group.
The study follows an interventional, randomized, parallel assignment model with no masking. Its primary purpose is treatment, focusing on comparing the effectiveness of the new drug regimen against the standard therapy.
The trial commenced on October 25, 2021, and is currently active but not recruiting. The last update was submitted on August 1, 2025. These dates are crucial as they provide a timeline for the study’s progress and expected completion.
This clinical update could influence AstraZeneca’s stock performance by potentially enhancing investor confidence if the results demonstrate significant benefits over existing treatments. The competitive landscape in oncology treatments, particularly for breast cancer, could see shifts depending on the outcomes of this study.
The study is ongoing, with further details available on the ClinicalTrials portal.